专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明公开

KR1020060095435A 발리다마이신 생합성 유전자군의 염기서열, 이를 이용한알파-글루코시데이즈 억제물질 생산 균주의 제조 및알파-글루코시데이즈 억제물질의 대량생산방법 失效
标题翻译：有效的生物降解基因簇的核苷酸序列，由COSMID HARBING THE CLUSTER转化的产生ALPHA-葡糖苷酶抑制剂的溶菌酶菌株的制备以及这些抑制剂的生产方法
公开(公告)号：KR1020060095435A
公开(公告)日：2006-08-31
申请号：KR1020050090434
申请日：2005-09-28
申请人： 명지대학교 산학협력단 , 서주원 , 주식회사 씨트리
发明人： 김순옥 , 현창구 , 허진행 , 서명지 , 서주원 , 권형진 , 신디팍 , 라즈카니카르,어리스마
IPC分类号： C12N15/31 , C12N15/52
摘要： 본 발명은 발리다마이신 생합성 유전자군의 염기서열, 이를 이용한 알파-글루코시데이즈 억제물질 생산균주의 제조 및 알파-글루코시데이즈 억제물질의 대량생산방법에 관한 것으로, 발리다마이신 생산균주인 스트렙토마이세스 하이그로스코피쿠스(
Streptomyces
hygroscopicus )
KCTC 1717에서 유래하고,
vldA 에서
vldM 까지 13개의 효소 코딩 유전자 지역을 포함하고, 인근지역의 12개의 효소 코딩 유전자 지역을 포함하여 총 25개의 유전자 코딩 지역으로 구성되는 약 37kb의 발리다마이신 생합성 유전자군의 염기서열을 제공하는 뛰어난 효과가 있다.
또한, 본 발명은 상기 발리다마이신 생합성 유전자군의 전체 또는 단편의 염기서열을 도입하여 알파-글루코시데이즈 억제활성을 갖는 스트렙토마이세스속 균주 유래의 형질전환체를 제조하고, 이로부터 발리엔아민 또는 발리올라민을 생산하는 방법을 제공하는 뛰어난 효과가 있다.
발리다마이신, 알파-글루코시데이즈 억제물질, 발리엔아민, 발리올라민

52. 发明授权

KR100593849B1 발리엔아민의 제조방법 有权
标题翻译：维胺胺的制备方法
公开(公告)号：KR100593849B1
公开(公告)日：2006-06-28
申请号：KR1020050036755
申请日：2005-05-02
申请人： 주식회사 씨트리
发明人： 변일석 , 김주성 , 신성혜 , 김완주
IPC分类号： C07C213/08
摘要： 본 발명은 아카보스 또는 아카보스 유도체를 염기의 존재하에서 반응시켜 하기 화학식 (1)로 표시되는 발리엔아민(Valienamine)을 제조하는 방법에 관한 것이다.

(1)
보글리보스, 발리엔아민, 아카보스, 가수분해, 염기
摘要翻译：本发明涉及阿卡波糖或阿卡波糖衍生物在碱的存在下反应，一种制备由式（1）表示的烯胺巴厘岛（Valienamine）。

53. 发明公开

KR1020040079136A 인간 로타바이러스의 활성을 저해하는 항체의 생산용 항원및 그의 제조방법과 이용 无效
标题翻译：用于生产具有改善特异性的人类脊髓灰质炎抗体的抗原和抗原制备及其用途
公开(公告)号：KR1020040079136A
公开(公告)日：2004-09-14
申请号：KR1020030014070
申请日：2003-03-06
申请人： 주식회사 씨트리
发明人： 박희정 , 김승영 , 김순옥 , 장석구 , 김완주
IPC分类号： C12N15/70
CPC分类号： C07K14/005 , A23L33/10 , A23V2002/00 , A23V2200/324 , A61K35/57 , C07K16/10 , C07K2317/23 , C12N15/70 , C12N2720/12333
摘要： PURPOSE: An antigen and antigen preparation for the production of the antibody against human rotavirus, and the use thereof are provided, thereby mass-producing the antigen, and cheaply producing the antibody against human rotavirus having improved specificity from the egg yolk. CONSTITUTION: The antigen preparation for the production of the antibody against human rotavirus comprises the steps of: (a) RT-PCR amplifying the genomic RNA of human rotavirus as a template using a primer of SEQ ID NO:1 or SEQ ID NO:2 to selectively isolate a gene encoding VP8 antigen protein; (b) cloning the isolated gene into a vector, and transforming a microorganism with the vector to extract the DNA of the vector; (c) PCR amplifying the extracted vector DNA using primers of SEQ ID NO:3 and SEQ ID NO:4 to amplify the gene encoding the VP8 antigen protein; (d) cloning the amplified gene into an expression vector pET-29b and transforming Escherichia coli with the vector; and (e) culturing the transformed E. coli to over-express VP8 antigen protein and purifying the VP8 antigen protein by using the Ni+-NTA affinity column.
摘要翻译：目的：提供用于产生针对人轮状病毒的抗体的抗原和抗原制剂及其用途，从而批量生产抗原，并且廉价地生产具有改善的蛋黄特异性的抗轮状病毒抗体。构成：用于产生针对人轮状病毒的抗体的抗原制备方法包括以下步骤：（a）使用SEQ ID NO：1或SEQ ID NO：2的引物RT-PCR扩增人轮状病毒的基因组RNA作为模板选择性分离编码VP8抗原蛋白的基因; （b）将分离的基因克隆到载体中，并用载体转化微生物以提取载体的DNA; （c）使用SEQ ID NO：3和SEQ ID NO：4的引物PCR扩增提取的载体DNA以扩增编码VP8抗原蛋白的基因; （d）将扩增的基因克隆到表达载体pET-29b中并用载体转化大肠杆菌; 和（e）培养转化的大肠杆菌以过表达VP8抗原蛋白，并使用Ni + -NTA亲和柱纯化VP8抗原蛋白。

54. 发明公开

KR1020040007550A 신규한 알카로이드 유도체 및 이를 함유하는 약제학적조성물 失效
标题翻译：新型碱性衍生物和含有它们的药物组合物
公开(公告)号：KR1020040007550A
公开(公告)日：2004-01-24
申请号：KR1020037014670
申请日：2002-05-27
申请人： 주식회사 씨트리 , 주식회사 케이티앤지
发明人： 김완주 , 김경수 , 김명화 , 박종억 , 장정민 , 최재원 , 김동후 , 이재상 , 장동조 , 윤은영 , 김순옥 , 장석구
IPC分类号： C07C323/41
CPC分类号： C07C69/78 , C07C49/755 , C07C203/10 , C07C233/32 , C07C233/41 , C07C233/76 , C07C235/14 , C07C235/42 , C07C271/24 , C07C323/41 , C07C323/42 , C07C2603/34 , C07D307/93
摘要： PURPOSE: Novel alkaloid derivatives, specifically novel colchicine derivatives having anticancer, antiproliferative and anti-inflammatory effects, and immunosuppressive function and muscle relaxation, and a pharmaceutical composition containing the same are provided. CONSTITUTION: The novel colchicine derivatives have the formula (I), wherein, if R1 is N(R6)C(X1)-A, X2C(X1)-A, N(R6)-A, N(A)2 or X2-A, R2 is X3R7 or N(R7)2, R3 and R4 are independently hydrogen or a methyl group, R5 is hydrogen, a methyl group, or CH2X4R7, wherein R6 and R7 are independently hydrogen or a lower alkyl group, and X, X1, X2, X3 and X4 are independently 0 or S; if R2 is N(R6)C(X1)-A, X2C(X1)-A, N(R6)-A, N(A)2 or X2-A, R1 is N(R6)COCH3, N(R6)COCF3, or NHC(O)OR8, R3 and R4 are independently hydrogen or a methyl group, R5 is hydrogen, a methyl group, or CH2X4R7, wherein R6 and R7 are independently hydrogen or a lower alkyl group, R8 is a lower alkyl, alkenyl, or substituted or unsubstituted aryl, and X, X1, X2 and X4 are independently 0 or S; if R3 and R4 are independently C(X1)-A or -A, R1 is N(R6)COCH3, N(R6)COCF3, or NHC(O)OR8, R2 is X3R7 or N(R-)2, R5 is hydrogen, a methyl group, or CH2X4R7, wherein R6 and R7 are independently hydrogen or a lower alkyl group, R8 is a lower alkyl, alkenyl, or substituted or unsubstituted aryl, and X, X1, X3 or X4 are independently 0 or S; and if R5 is CH2X2C(X1)-A, R1 is N(R6)COCH3, N(R6)COCF3 or NHC(O)OR8, R2 is X3R7 or N(R7)2, R3 and R4 are independently hydrogen or a methyl group, wherein R6 and R7 are independently hydrogen or a lower alkyl group, R8 is a lower alkyl, alkenyl, or substituted or unsubstituted aryl group, and X, X1, X2 and X3 are independently 0 or S, wherein A is represented by the formula (a), (b), (c), (d), (e), (g), (h), (i) or (j).
摘要翻译：目的：提供具有抗癌，抗增殖和抗炎作用，免疫抑制功能和肌肉松弛的新型生物碱衍生物，特别是具有新颖的秋水仙素衍生物，以及包含其的药物组合物。构型：新型秋水仙碱衍生物具有式（I），其中，如果R1是N（R6）C（X1）-A，X2C（X1）-A，N（R6）-A，N（A）2或X2 -A，R2是X3R7或N（R7）2，R3和R4独立地是氢或甲基，R5是氢，甲基或CH2X4R7，其中R6和R7独立地是氢或低级烷基，X X1，X2，X3和X4独立地为0或S; 如果R2是N（R6）C（X1）-A，X2C（X1）-A，N（R6）-A，N（A）2或X2-A，R1是N（R6）COCH3，N（R6） COCF 3或NHC（O）OR 8，R 3和R 4独立地是氢或甲基，R 5是氢，甲基或CH 2 X 4 R 7，其中R 6和R 7独立地是氢或低级烷基，R 8是低级烷基，烯基或取代或未取代的芳基，X，X1，X2和X4独立地为0或S; 如果R3和R4独立地为C（X1）-A或-A，R1为N（R6）COCH3，N（R6）COCF3或NHC（O）OR8，R2为X3R7或N（R-）2，R5为氢，甲基或CH2X4R7，其中R6和R7独立地是氢或低级烷基，R8是低级烷基，烯基或取代或未取代的芳基，X，X1，X3或X4独立地为0或S; 并且如果R 5为CH 2 X 2 C（X 1）-A，则R 1为N（R 6）COCH 3，N（R 6）COCF 3或NHC（O）OR 8，R 2为X 3 R 7或N（R 7）2，R 3和R 4独立地为氢或甲基基团，其中R6和R7独立地是氢或低级烷基，R8是低级烷基，烯基或取代或未取代的芳基，X，X1，X2和X3独立地是0或S，其中A由式（a），（b），（c），（d），（e），（g），（h），（i）或（j）

55. 发明公开

KR1020030042373A 키랄 2,2-디메틸시클로프로판카르복실의 유도체의 제조방법 失效
标题翻译：制备丙二醇二环丙基羧酸衍生物的方法
公开(公告)号：KR1020030042373A
公开(公告)日：2003-05-28
申请号：KR1020010073114
申请日：2001-11-22
申请人： 주식회사 씨트리 , 동국제약 주식회사
发明人： 변일석 , 김주성 , 이우화 , 김영윤 , 차경회 , 장석구 , 김완주
IPC分类号： C07D263/06
CPC分类号： C07D263/26 , C07B2200/07 , C07C51/487 , C07C61/04
摘要： PURPOSE: A process for preparing chiral 2,2-dimethyl cyclopropane carboxyl derivatives is provided, high purity of chiral 2,2-dimethyl cyclopropane carboxyl derivatives can be easily mass-produced by using a chiral hetero ring compound of formula 3 as a beam splitter. CONSTITUTION: The process for preparing chiral 2,2-dimethyl cyclopropane carboxyl derivatives of the formula(1) comprises the steps of: reacting (RS)-2,2-dimethyl cyclopropane carbonic acid(2) with a beam splitter to prepare a partial stereoisomer; and separating the partial stereoisomer by using crystallization or chromatography to prepare (R)-2,2-dimethyl cyclopropane carboxyl derivatives(1a) and (S)-2,2-dimethyl cyclopropane carboxyl derivatives(1b), wherein the beam splitter is the chiral hetero ring compound of formula(3); X is O or S; Y is O, S or N-R5; R5 is C1-C6 alkyl, or C1-C6 alkoxy or halogen substituted or unsubstituted aryl; R1, R2, R3 and R4 are independently H, C1-C6 alkyl, C1-C6 alkoxy or halogen substituted or unsubstituted aryl, or R6-O-CH2; and R6 is C1-C6 alkyl, or C1-C6 alkoxy or halogen substituted or unsubstituted aryl.
摘要翻译：目的：提供一种制备手性2,2-二甲基环丙烷羧基衍生物的方法，通过使用式3的手性杂环化合物作为分束器，可以容易地大规模生产手性2,2-二甲基环丙烷羧基衍生物的高纯度。构成：制备式（1）的手性2,2-二甲基环丙烷羧基衍生物的方法包括以下步骤：使（RS）-2,2-二甲基环丙烷碳酸（2）与分束器反应以制备部分立体异构体; 并通过使用结晶或色谱分离部分立体异构体制备（R）-2,2-二甲基环丙烷羧基衍生物（1a）和（S）-2,2-二甲基环丙烷羧基衍生物（1b），其中分束器是式（3）的手性杂环化合物; X是O或S; Y是O，S或N-R5; R5是C1-C6烷基或C1-C6烷氧基或卤素取代或未取代的芳基; R1，R2，R3和R4独立地为H，C1-C6烷基，C1-C6烷氧基或卤素取代或未取代的芳基或R6-O-CH2; 并且R 6是C 1 -C 6烷基或C 1 -C 6烷氧基或卤素取代或未取代的芳基。

56. 发明授权

KR100380393B1 일산화질소-매개 아폽토시스 조절제 및 이를 이용한일산화질소-매개 아폽토시스 조절방법 失效
标题翻译： 일산화질소 - 개아폽토시스조절제및이를이용한일산화질소 - 매개아폽토시스조절방
公开(公告)号：KR100380393B1
公开(公告)日：2003-04-16
申请号：KR1020000059332
申请日：2000-10-09
申请人： 정헌택 , 김영명 , 주식회사 씨트리
发明人： 정헌택 , 김영명 , 김완주
IPC分类号： A61K33/26
摘要： PURPOSE: A method for controlling nitrogen monoxide-mediated apoptosis by increasing a DNIC(dinitrosyl-iron complex) content in a cell by the treatment of Fe¬2+ in the cell or directly treating DNIC is provided. It can be used in the treatment of diseases associated with apoptosis of the cell induced by nitrogen monoxide. CONSTITUTION: Dinitrosyl-iron complexes are used as a nitrogen monoxide-mediated apoptosis-controlling agent. The nitrogen monoxide-mediated apoptosis is controlled by inhibiting the activity of caspase by increasing the content of dinitrosyl-iron complexes in a cell. The increase in the content of dinitrosyl-iron complexes in the cell is achieved by direct treatment of DNIC or DNIC-containing cytosol separated from the cell, or treatment of Fe¬2+ or a salt containing the same in the cell.
摘要翻译：目的：提供一种通过在细胞中通过处理Fe 2+ 2+或直接处理DNIC来增加细胞中的DNIC（二亚硝基铁络合物）含量来控制一氧化氮介导的细胞凋亡的方法。它可以用于治疗与一氧化氮诱导的细胞凋亡有关的疾病。构成：二亚硝酰铁复合物用作一氧化氮介导的凋亡控制剂。一氧化氮介导的细胞凋亡通过增加细胞中二亚硝酰 - 铁复合物的含量来抑制胱天蛋白酶的活性来控制。通过直接处理从细胞分离的含DNIC或含DNIC的细胞溶质，或在细胞中处理Fe 2+或含有它们的盐，实现细胞中二亚硝酰 - 铁复合物含量的增加。

57. 发明公开

KR1020030026654A 인간 로타바이러스의 활성을 저해하는 항체의 생산용 항원및 그의 제조방법과 이용 无效
标题翻译：用于生产人类脊髓灰质炎抗生素抑制活性的抗原及其生产及其使用
公开(公告)号：KR1020030026654A
公开(公告)日：2003-04-03
申请号：KR1020010059731
申请日：2001-09-26
申请人： 주식회사 씨트리
发明人： 이석준 , 김희주 , 윤순대 , 김순옥 , 김경수 , 김완주
IPC分类号： A61K39/15
摘要： PURPOSE: A process of mass-preparing a specific antigen used for production of an antibody which inhibits the activity of human rotavirus causing diarrhea is provided. The obtained eggs from birds immunized with the antigen have prevention and treatment effects on diarrhea. A functional food containing the egg yolk of the eggs has preventive and therapeutic effects on diarrhea in an infant and a young child. CONSTITUTION: The mass producing method of the specific antigen comprises the step of: selectively separating a gene encoding VP7 antigen by performing RT PCR using, as a template, genomic DNA of human rotavirus; extracting vector DNA by inserting the separated gene into a suitable vector, transforming a suitable strain with the vector and amplifying the vector; amplifying the gene encoding the antigen protein by performing PCR using, as a template, the extracted vector DNA; cloning the amplified gene into a suitable vector and transforming a suitable host with the vector; and culturing the host, followed by overexpressing the antigen.
摘要翻译：目的：提供一种大规模制备用于制备抑制引起腹泻的人轮状病毒活性的抗体的特异性抗原的方法。用抗原免疫的鸟获得的鸡蛋具有对腹泻的预防和治疗作用。含有鸡蛋蛋白的功能性食物对婴儿和幼儿的腹泻具有预防和治疗作用。构成：特定抗原的批量生产方法包括以下步骤：使用人轮状病毒的基因组DNA作为模板，通过进行RT PCR选择性分离编码VP7抗原的基因; 通过将分离的基因插入合适的载体中来提取载体DNA，用载体转化合适的菌株并扩增载体; 通过使用提取的载体DNA作为模板进行PCR来扩增编码抗原蛋白的基因; 将扩增的基因克隆到合适的载体中并用载体转化合适的宿主; 并培养宿主，然后过表达抗原。

58. 发明公开

KR1020020074802A 항체 함유 난황분말의 제조방법, 이로부터 제조된 난황분말 및 난황분말 함유 조성물 失效
标题翻译：生产含有抗菌剂的蛋黄粉，含有蛋黄粉的蛋黄粉和含有蛋黄粉的组合物
公开(公告)号：KR1020020074802A
公开(公告)日：2002-10-04
申请号：KR1020010014825
申请日：2001-03-22
申请人： 주식회사 씨트리
发明人： 김순옥 , 유선영 , 석철준 , 배윤의 , 이석준 , 김희주 , 김완주
IPC分类号： A61K39/395
摘要： PURPOSE: A process of preparing egg yolk powder containing antibodies treated with a grapefruit seed extract to maintain the potency of antibodies and to increase preservability and an additive to remove a fishy smell in the yolk and to increase the flavor and preservability thereof is provided. Because the composition containing the egg yolk powder is power, it is convenient to handle and take and can also be encapsulated. CONSTITUTION: The antibodies induced from strains causing various diseases in mammals are injected to laying hens. An egg yolk liquid containing an antibody is separated from the egg produced from the immunized laying hens, added with 250 to 1,000ppm grapefruit extract and 5 to 15% by weight of white sugar and heated at 60 to 70deg.C for 3 to 10min one to three times. The heat treated egg yolk liquid is spray-dried or freeze-dried. The composition comprises 40 to 50% by weight of egg yolk powder, 45 to 55% by weight of lactic acid powder, 0.5 to 1.5% by weight of silica dioxide, 0.5 to 1.5% by weight of magnesium stearate and 0.1 to 2% by weight of a sweetener.
摘要翻译：目的：提供含有用葡萄柚种子提取物处理的抗体的蛋黄粉的制备方法，以维持抗体的效力和提高保存性，并提供除去蛋黄中的鱼腥味的添加剂和增加其风味和保存性。因为含有蛋黄粉的成分是动力，所以处理和取出也是可以被包装的。构成：将哺乳动物引起各种疾病的菌株引起的抗体注射到产蛋鸡。将含有抗体的蛋黄液与从免疫的产蛋鸡产生的蛋分离，加入250至1,000ppm葡萄柚提取物和5至15重量％的白糖，并在60至70℃下加热3至10分钟到三次。将经热处理的蛋黄液体喷雾干燥或冷冻干燥。该组合物包含40〜50重量％的蛋黄粉，45〜55重量％的乳酸粉，0.5〜1.5重量％的二氧化硅，0.5〜1.5重量％的硬脂酸镁和0.1〜2重量％的甜味剂的重量。

59. 发明公开

KR1020010073460A 1,3-벤조디티올-2-일리움 테트라플루오로보레이트의제조방법 失效
标题翻译：生产1,3-二苯并二氢吡喃酮（BDTF）的方法
公开(公告)号：KR1020010073460A
公开(公告)日：2001-08-01
申请号：KR1020000001859
申请日：2000-01-15
申请人： 주식회사 씨트리
发明人： 이태석 , 유창현 , 김경수 , 유정복 , 박성준 , 김완주
IPC分类号： C07D339/06
摘要： PURPOSE: A method for producing 1,3-benzodithiol-2-ilium tetrafluoroborate(BDTF) is provided, thereby the crystalline BDTF having the improved stability and light color can be easily and simply produced in higher yield. CONSTITUTION: The method for producing 1,3-benzodithiol-2-ilium tetrafluoroborate(BDTF) represented by the formula (I) comprises the steps of: preparing 2-(3-methylbutoxy)-1,3-benzodithiol represented by the formula (II) from the anthranilic acid dissolved 1,4-dioxane and continuously adding a nonquantum and nonpolar organic solvent selected from the group consisting of diethylether, THF, toluene, chloroform, hexane, cyclohexane and diisopropylether, and simultaneously adding BF4 or Et2O·BF3 into the compound of the formula (II).
摘要翻译：目的：提供一种生产1,3-苯并二硫醇-2-铱四氟硼酸盐（BDTF）的方法，由此可以容易且简单地以更高的产率生产具有改善的稳定性和浅色的结晶BDTF。构成：由式（I）表示的1,3-苯并二硫醇-2-铱四氟硼酸盐（BDTF）的制备方法包括以下步骤：制备由式（I）表示的2-（3-甲基丁氧基）-1,3-苯并二硫醇 II），连续加入选自二乙醚，THF，甲苯，氯仿，己烷，环己烷和二异丙醚的非极性和非极性有机溶剂，并同时加入BF 4或Et 2 O·BF 3 式（II）的化合物。

60. 发明授权

KR100293121B1 항진균제용 터비나핀 및 그 염산염의 제조방법 有权
标题翻译：特比萘芬及其盐酸盐作为抗真菌剂的制备方法
公开(公告)号：KR100293121B1
公开(公告)日：2001-06-15
申请号：KR1019990012298
申请日：1999-04-08
申请人： 주식회사 씨트리 , 한솔케미언스 주식회사 , 고려제약주식회사
发明人： 이태석 , 안현숙 , 유창현 , 김경수 , 육진수 , 오성수 , 주소경 , 김완주
IPC分类号： C07C209/68
摘要： 본발명은항진균제로서광범위한약효를갖는다음의구조식 (I)과 (Ia)로표시되는터비나핀및 그염산염의신규한제조방법을제공하기위한것이다. 본발명의방법은각 반응단계에서가장반응성이좋은촉매를선택함으로써하나의반응기에서약 2 내지 4시간의짧은시간내에반응을효율적으로수행하여터비나핀염산염을고순도, 고수율(약 70.5%)로합성하는것이다.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式